PROTARA THERAPEUTICS, INC.

Analyst Reco. Protara Therapeutics, Inc.

Equities

TARA

US74365U1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-31 pm EDT			5-day change	1st Jan Change
2.81 ^USD	-3.10%		+0.36%	+49.86%

May. 02	Protara Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Protara Therapeutics, Inc. announced that it has received $44.998327 million in funding from a group of investors	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oppenheimer Adjusts Protara Therapeutics Price Target to $30 From $26	Apr. 22	MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $30, Maintains Outperform Rating	Nov. 06	MT
Guggenheim Assumes Protara Therapeutics at Buy With $22 Price Target	23-07-10	MT
HC Wainwright Cuts Protara Therapeutics' Price Target to $23 From $30, Maintains Buy Rating	22-08-10	MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $26 From $32, Maintains Outperform Rating	22-05-11	MT
HC Wainwright Lowers Protara Therapeutics Price Target to $30 From $40, Buy Rating Kept	22-05-09	MT
Oppenheimer Adjusts Protara Therapeutics Price Target to $32 From $34, Maintains Outperform Rating	22-03-14	MT
Oppenheimer Adjusts Price Target on Protara Therapeutics to $34 from $32, Keeps Outperform Rating	21-11-08	MT
PROTARA THERAPEUTICS : BofA Securities Starts Protara Therapeutics at Buy With $15 Price Target	21-08-30	MT
PROTARA THERAPEUTICS : HC Wainwright Starts Protara Therapeutics at Buy With $40 Price Target	21-06-04	MT
PROTARA THERAPEUTICS : Oppenheimer Adjusts Protara Therapeutics PT to $32 From $43, Maintains Outperform Rating	21-04-26	MT
PROTARA THERAPEUTICS : Oppenheimer Initiates Coverage on Protara Therapeutics With Outperform Rating, $43 Price Target	21-02-17	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer